Pluristem's PLX Cells Demonstrate Efficacy in Preliminary Animal Experiment for Graft vs Host Disease

Pluristem Therapeutics (NASDAQ: PSTI ) announced today that the company's PLacental eXpanded (PLX) cells demonstrated efficacy in a preliminary animal experiment for the treatment of Graft versus Host Disease (GvHD) following bone marrow transplantation (BMT). The results showed that PLX cells, regardless of their administration route, intravenous (IV) or